SeaStar Medical Expands Acute Kidney Injury Treatment Strategy with Promising Q1 Performance
SeaStar Medical reports significant growth in pediatric acute kidney injury treatment QUELIMMUNE and advances plans to enter the larger adult market, with potential to address a $4.5 billion annual opportunity.
Medical device company SeaStar Medical demonstrated substantial revenue growth in its first quarter of 2025, with QUELIMMUNE sales increasing fourfold to $293,000 and the company positioning itself to expand into the adult acute kidney injury (AKI) treatment market.
The company's breakthrough product, QUELIMMUNE, is currently FDA-approved for pediatric AKI treatment and represents a potential life-saving therapy for critically ill patients. While the pediatric market represents approximately 4,000 patients annually, SeaStar is targeting the significantly larger adult AKI market, estimated at a $4.5 billion annual opportunity.
The company's NEUTRALIZE-AKI pivotal trial for adult patients is currently 50% enrolled, with potential FDA approval anticipated in 2026. This trial evaluates the safety and efficacy of the company's Selective Cytopheretic Device (SCD) therapy in treating adult AKI patients in intensive care units.
Financial performance also showed improvement, with the company's net loss narrowing to $3.8 million in the first quarter, compared to $12.7 million in the same quarter of the previous year. SeaStar concluded the quarter with $5.3 million in cash, bolstered by a $6 million registered direct offering.
CEO Eric Schlorff emphasized the company's commitment to expanding its market presence and developing treatments that can potentially spare organs and save lives for critically ill patients. The company continues to attract new customers and has received two additional Breakthrough Device Designations, bringing its total to six therapeutic indications.